WO1996039147A3 - Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases - Google Patents

Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases Download PDF

Info

Publication number
WO1996039147A3
WO1996039147A3 PCT/US1996/006289 US9606289W WO9639147A3 WO 1996039147 A3 WO1996039147 A3 WO 1996039147A3 US 9606289 W US9606289 W US 9606289W WO 9639147 A3 WO9639147 A3 WO 9639147A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye diseases
topical ophthalmic
ophthalmic formulations
treating allergic
formulations containing
Prior art date
Application number
PCT/US1996/006289
Other languages
French (fr)
Other versions
WO1996039147A2 (en
Inventor
John Michael Yanni
Stella M Robertson
Eiji Hayakawa
Masashi Nakakura
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23864859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1996039147(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP9500510A priority Critical patent/JP3068858B2/en
Priority to AU57261/96A priority patent/AU698854B2/en
Priority to KR1019970700721A priority patent/KR100202155B1/en
Priority to DK96915500T priority patent/DK0799044T3/en
Priority to DE69622527T priority patent/DE69622527T2/en
Priority to AT96915500T priority patent/ATE220906T1/en
Priority to EP96915500A priority patent/EP0799044B1/en
Priority to DE2002199034 priority patent/DE10299034I2/en
Priority to CA002195094A priority patent/CA2195094C/en
Priority to MX9701013A priority patent/MX9701013A/en
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of WO1996039147A2 publication Critical patent/WO1996039147A2/en
Priority to FI970489A priority patent/FI970489A0/en
Priority to NO19970517A priority patent/NO311637B1/en
Publication of WO1996039147A3 publication Critical patent/WO1996039147A3/en
Priority to NL300101C priority patent/NL300101I2/en
Priority to LU90969C priority patent/LU90969I2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
PCT/US1996/006289 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases WO1996039147A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DE2002199034 DE10299034I2 (en) 1995-06-06 1996-05-03 Formulation for topical use on the eye containing olopatadine for the treatment of allergic eye diseases.
MX9701013A MX9701013A (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases.
CA002195094A CA2195094C (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases
DK96915500T DK0799044T3 (en) 1995-06-06 1996-05-03 Topical ophthalmological formulations containing olopatidine for the treatment of allergic eye diseases
AU57261/96A AU698854B2 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases
AT96915500T ATE220906T1 (en) 1995-06-06 1996-05-03 TOPICAL EYE FORMULATION CONTAINING OLOPATADINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES
EP96915500A EP0799044B1 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing olopatadine for treating allergic eye diseases
JP9500510A JP3068858B2 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases
KR1019970700721A KR100202155B1 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxetin derivatives for treating allergic eye diseases
DE69622527T DE69622527T2 (en) 1995-06-06 1996-05-03 FORMULA FOR TOPICAL APPLICATION ON THE EYE CONTAINING OLOPATADINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES
NO19970517A NO311637B1 (en) 1995-06-06 1997-02-05 Topical ophthalmic formulations containing doxepin derivatives for the treatment of ocular allergy diseases
FI970489A FI970489A0 (en) 1995-06-06 1997-02-05 Topical ophthalmic compositions containing doxepin derivatives and suitable for the treatment of allergic ocular diseases
NL300101C NL300101I2 (en) 1995-06-06 2002-09-19 Topically ophthalmic formulations containing olopatadine for it
LU90969C LU90969I2 (en) 1995-06-06 2002-10-02 Topical ophthalmic compositions containing olopatadine for the treatment of allergic eye conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,729 1995-06-06
US08/469,729 US5641805A (en) 1995-06-06 1995-06-06 Topical ophthalmic formulations for treating allergic eye diseases

Publications (2)

Publication Number Publication Date
WO1996039147A2 WO1996039147A2 (en) 1996-12-12
WO1996039147A3 true WO1996039147A3 (en) 1997-02-20

Family

ID=23864859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/006289 WO1996039147A2 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases

Country Status (20)

Country Link
US (1) US5641805A (en)
EP (1) EP0799044B1 (en)
JP (1) JP3068858B2 (en)
KR (1) KR100202155B1 (en)
CN (1) CN1082367C (en)
AT (1) ATE220906T1 (en)
AU (1) AU698854B2 (en)
CA (1) CA2195094C (en)
DE (2) DE69622527T2 (en)
DK (1) DK0799044T3 (en)
ES (1) ES2179198T3 (en)
FI (1) FI970489A0 (en)
LU (1) LU90969I2 (en)
MX (1) MX9701013A (en)
MY (1) MY116651A (en)
NL (1) NL300101I2 (en)
NO (1) NO311637B1 (en)
PT (1) PT799044E (en)
TW (1) TW438588B (en)
WO (1) WO1996039147A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
ES2159209T3 (en) * 1998-07-14 2001-09-16 Alcon Lab Inc USE OF ACID 11- (3-DIMETHYLAMOPROPILIDEN) -6,11-DIHIDRODIBENZ (B, E) OXEPIN-2-ACETIC AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NON-ALBUM ADMINISTRATION OF OCULAR NEOVASCULARIZATION.
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
ES2213001T3 (en) 1999-06-18 2004-08-16 Alcon Manufacturing Ltd. METHOD FOR SELECTING THE CONCENTRATION OF AN ANTIHISTAMINAL ANPHIPATHIC PHARMACO BY DETERMINING THE VALUE OF SURFACE ACTIVITY OF THE FARMACO.
DE60109742T2 (en) 2000-01-25 2005-08-18 Alcon Inc. ANTIALLERGIC OPHTHALMIC PREPARATIONS, SUITABLE FOR USE WITH CONTACT LENSES
EP1289945B1 (en) 2000-05-19 2004-08-04 Alcon Inc. Aniline disulfide derivatives for treating allergic diseases
BR0110852A (en) 2000-05-19 2003-02-11 Alcon Inc Compositions containing a benzamide disulfide derivative for treatment of allergic diseases
PL365457A1 (en) 2000-05-19 2005-01-10 Alcon, Inc. Disulfide derivatives useful for treating allergic diseases
WO2002089615A2 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
PL369630A1 (en) * 2001-12-05 2005-05-02 Alcon, Inc. Use of a h1 antagonist and rimexolone as a safe steroid to treat rhinitis
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
KR20070024618A (en) * 2004-06-28 2007-03-02 알콘, 인코퍼레이티드 Topical formulations for treating allergic diseases
MX2007005845A (en) * 2004-11-24 2007-07-04 Alcon Inc Method of delivering nasal spray.
EP1901708B1 (en) 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
EP2004196B1 (en) 2006-03-31 2016-06-29 Vistakon Pharmaceuticals, LLC Ocular allergy treatments
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
SI2114367T1 (en) 2007-02-07 2016-01-29 Novartis Ag Olopatadine formulations for topical nasal administration
AR066016A1 (en) * 2007-04-11 2009-07-15 Alcon Res Ltd USE OF AN ALFA TNF INHIBITOR TOGETHER WITH AN ANTIHISTAMINE TO TREAT ALLERGIC RHINITIS AND ALLERGIC CONJUNCTIVITIS
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
JP5307015B2 (en) * 2007-09-06 2013-10-02 協和発酵キリン株式会社 Eye drops containing dibenzo [b, e] oxepin derivatives
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
IT1397503B1 (en) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint PROCESS FOR THE PREPARATION OF OLOPATADIN
CN102470099A (en) 2009-07-17 2012-05-23 爱尔康研究有限公司 Olopatadine nasal spray regimen for children
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
CA2773483A1 (en) 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
TWI544922B (en) * 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration olopatadine ophthalmic composition
CN103202833A (en) * 2012-12-25 2013-07-17 常州市亚邦医药研究所有限公司 Pharmaceutical composition of olopatadine or salts of olopatadine, and preparation method thereof
US20150119455A1 (en) * 2013-10-31 2015-04-30 Nephron Pharmaceuticals Corporation Formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0048023A2 (en) * 1980-09-17 1982-03-24 Joel E. Bernstein, M.D. Composition for treating and preventing irritation of the eyes
EP0214779A1 (en) * 1985-08-17 1987-03-18 The Wellcome Foundation Limited Tricyclic compounds
EP0235796A2 (en) * 1986-03-03 1987-09-09 Kyowa Hakko Kogyo Co., Ltd. Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0048023A2 (en) * 1980-09-17 1982-03-24 Joel E. Bernstein, M.D. Composition for treating and preventing irritation of the eyes
EP0214779A1 (en) * 1985-08-17 1987-03-18 The Wellcome Foundation Limited Tricyclic compounds
EP0235796A2 (en) * 1986-03-03 1987-09-09 Kyowa Hakko Kogyo Co., Ltd. Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ATARASHII GANKA, vol. 11, no. 4, 1994, pages 603 - 5 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAMEI, CHIAKI ET AL: "Effects of certain anti-allergic drugs on experimental conjunctivitis in guinea pigs", XP002021562 *
KAMEI C ET AL: "Effect of (Z)-11-[3-(dimethylamino) propylidene]-6,11-dihydrodibenz[b,e ]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs.", ARZNEIMITTELFORSCHUNG, SEP 1995, 45 (9) P1005-8, GERMANY, XP000615221 *
OHSHIMA, ETSUO ET AL: "Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz(b,e)oxepin derivatives", J. MED. CHEM., 1992, 2074-84, XP000615220 *
SHARIF N A ET AL: "Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 278 (3). 1996. 1252-1261., XP000613049 *
SHARIF N A ET AL: "Olopatadine (AL-4943A): Pharmacological profile of a novel anti-histamine-anti-allergic drug for use in allergic conjunctivitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 37 (3). 1996. S1027., XP000613434 *
SPITALNY L ET AL: "Olopatadine ophthalmic solution decreases itching and redness associated with allergic conjunctivitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 37 (3). 1996. S593., XP000613433 *
YANNI J M ET AL: "The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic-antihistaminic agent", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 37 (3). 1996. S1028., XP000613432 *
ZHANG M.-Q. ET AL: "Optically active analogues of ebastine: Synthesis and effect of chirality on their antihistaminic and antimuscarinic activity", CHIRALITY, 1994, 6/8 (631-641), USA, XP000613077 *

Also Published As

Publication number Publication date
DE10299034I1 (en) 2003-01-23
NO970517L (en) 1997-04-03
AU5726196A (en) 1996-12-24
NO311637B1 (en) 2001-12-27
DK0799044T3 (en) 2002-10-14
NO970517D0 (en) 1997-02-05
CA2195094C (en) 2002-02-26
CN1161000A (en) 1997-10-01
US5641805A (en) 1997-06-24
EP0799044B1 (en) 2002-07-24
NL300101I2 (en) 2003-01-06
PT799044E (en) 2002-11-29
DE69622527D1 (en) 2002-08-29
MX9701013A (en) 1997-05-31
FI970489A (en) 1997-02-05
JP3068858B2 (en) 2000-07-24
LU90969I2 (en) 2002-12-02
AU698854B2 (en) 1998-11-12
WO1996039147A2 (en) 1996-12-12
NL300101I1 (en) 2002-12-02
TW438588B (en) 2001-06-07
DE69622527T2 (en) 2002-12-05
FI970489A0 (en) 1997-02-05
EP0799044A2 (en) 1997-10-08
ES2179198T3 (en) 2003-01-16
KR970704452A (en) 1997-09-06
CN1082367C (en) 2002-04-10
DE10299034I2 (en) 2005-07-07
MY116651A (en) 2004-03-31
KR100202155B1 (en) 1999-06-15
JPH09510235A (en) 1997-10-14
ATE220906T1 (en) 2002-08-15
CA2195094A1 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
WO1996039147A3 (en) Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases
CA2216796A1 (en) Quinazoline derivatives
EP0950402A3 (en) Chewable pharmaceutical composition with gelatin matrix
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
WO2001027111A3 (en) Bicyclic imidazo-3-yl-amine derivatives
CA2107669A1 (en) Preparation for treating wounds and hemorrhoides
AU6199494A (en) New polypeptide compound and a process for preparation thereof
CA2306393A1 (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
CA2190303A1 (en) Pharmaceutical composition, method and device for preventing or treating dry eye or disease caused therefrom
AU5910996A (en) Pyrrole derivatives and medicinal composition
WO2000078296A3 (en) Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2001027110A3 (en) Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring
AU5555596A (en) Method for treating dyskinesias
EP0842663A4 (en) Ophthalmic preparations
CA2272732A1 (en) Hemorrhoidal treatment composition
AU4976599A (en) Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2320627A1 (en) Medicament for treatment of diastolic dysfunction
CA2260863A1 (en) Treatment of psychotic disorders
AU7587396A (en) Ocular depressor
EP1172360A4 (en) Neurotrophin potentiators
AU1764300A (en) Novel derivatives of swainsonine, processes for their preparation, and their useas therapeutic agents
CA2340920A1 (en) A method for preventing the onset of asthma
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96190605.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN FI JP KR MX NO SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2195094

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1996915500

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019970700721

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 970489

Country of ref document: FI

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN FI JP KR MX NO SG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1019970700721

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996915500

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019970700721

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996915500

Country of ref document: EP